Hanson & Doremus Investment Management’s GSK GSK Stock Holding History

Hanson & Doremus Investment Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$91K	Hold	1,640	–	–	0.01%	273
2025 Q4	$80K	Sell	1,640 -59	-3%	-$2.75K	0.01%	280
2025 Q3	$73K	Sell	1,699 -1,007	-37%	-$39.3K	0.01%	290
2025 Q2	$104K	Buy	2,706 +1,299	+92%	+$49.6K	0.01%	258
2025 Q1	$55K	Buy	1,407 +831	+144%	+$30.4K	0.01%	307
2024 Q4	$19K	Hold	576	–	–	﹤0.01%	375
2024 Q3	$24K	Hold	576	–	–	﹤0.01%	347
2024 Q2	$22K	Hold	576	–	–	﹤0.01%	360
2024 Q1	$25K	Buy	+576	New	+$23.8K	﹤0.01%	354
2023 Q1	–	Sell	-448	Closed	-$16K	–	487
2022 Q4	$16K	Hold	448	–	–	﹤0.01%	415
2022 Q3	$13K	Hold	448	–	–	﹤0.01%	415
2022 Q2	$24K	Sell	448 -280	-38%	-$15.5K	0.01%	368
2022 Q1	$40K	Buy	728 +364	+100%	+$19.8K	0.01%	333
2021 Q4	$20K	Hold	364	–	–	﹤0.01%	378
2021 Q3	$17K	Sell	364 -25,081	-99%	-$1.26M	﹤0.01%	372
2021 Q2	$1.2M	Buy	25,445 +593	+2%	+$28.5K	0.36%	57
2021 Q1	$1.11M	Sell	24,852 -1,061	-4%	-$48.2K	0.26%	82
2020 Q4	$1.19M	Buy	25,913 +468	+2%	+$21.5K	0.3%	67
2020 Q3	$1.2M	Sell	25,445 -1,539	-6%	-$77.1K	0.36%	57
2020 Q2	$1.38M	Sell	26,984 -2,762	-9%	-$142K	0.44%	44
2020 Q1	$1.41M	Buy	29,746 +1,204	+4%	+$64.2K	0.48%	43
2019 Q4	$1.68M	Buy	28,542 +476	+2%	+$26.5K	0.48%	47
2019 Q3	$1.5M	Buy	28,066 +738	+3%	+$38K	0.47%	48
2019 Q2	$1.37M	Buy	27,328 +333	+1%	+$16.7K	0.43%	48
2019 Q1	$1.41M	Sell	26,995 -623	-2%	-$31.1K	0.46%	50
2018 Q4	$1.32M	Buy	27,618 +1,250	+5%	+$61.6K	0.48%	48
2018 Q3	$1.32M	Buy	26,368 +175	+0.7%	+$8.89K	0.41%	60
2018 Q2	$1.32M	Sell	26,193 -1,485	-5%	-$74.8K	0.43%	59
2018 Q1	$1.35M	Buy	27,678 +7,895	+40%	+$368K	0.42%	60
2017 Q4	$877K	Sell	19,783 -1,272	-6%	-$58.8K	0.29%	84
2017 Q3	$1.07M	Buy	21,055 +276	+1%	+$14K	0.37%	72
2017 Q2	$1.12M	Buy	20,779 +328	+2%	+$17.5K	0.41%	69
2017 Q1	$1.08M	Sell	20,451 -38	-0.2%	-$1.93K	0.43%	66
2016 Q4	$986K	Sell	20,489 -797	-4%	-$39.4K	0.43%	65
2016 Q3	$1.15M	Sell	21,286 -160	-0.7%	-$8.77K	0.53%	56
2016 Q2	$1.16M	Hold	21,446	–	–	0.53%	53
2016 Q1	$1.09M	Sell	21,446 -2,774	-11%	-$138K	0.49%	58
2015 Q4	$1.22M	Buy	24,220 +2,916	+14%	+$149K	0.55%	49
2015 Q3	$1.02M	Buy	21,304 +8	+0%	+$416	0.49%	56
2015 Q2	$1.11M	Buy	21,296 +288	+1%	+$16.2K	0.47%	61
2015 Q1	$1.21M	Buy	21,008 +448	+2%	+$25.7K	0.51%	58
2014 Q4	$1.1M	Buy	20,560 +1,883	+10%	+$105K	0.47%	62
2014 Q3	$1.07M	Buy	18,677 +12	+0.1%	+$736	0.49%	65
2014 Q2	$1.25M	Sell	18,665 -2,920	-14%	-$198K	0.57%	55
2014 Q1	$1.44M	Sell	21,585 -328	-1%	-$22.2K	0.68%	47
2013 Q4	$1.46M	Sell	21,913 -192	-0.9%	-$12.4K	0.7%	44
2013 Q3	$1.39M	Sell	22,105 -132	-0.6%	-$8.5K	0.7%	46
2013 Q2	$1.39M	Buy	+22,237	New	+$1.41M	0.76%	39

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hanson & Doremus Investment Management's GSK Position: Q1 2026 in Review

Hanson & Doremus Investment Management held its GSK (GSK) position steady in Q1 2026 at 1,640 shares worth $91K. The position accounts for 0.01% of the portfolio, ranked #273.

Hanson & Doremus Investment Management first reported a position in GSK in Q2 2013 and has held it in 48 quarters since. The position peaked at $1.68M in Q4 2019. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Hanson & Doremus Investment Management held 1,640 shares of GSK worth $91K as of Q1 2026.
Hanson & Doremus Investment Management left its GSK share count unchanged in Q1 2026.
GSK made up 0.01% of Hanson & Doremus Investment Management's portfolio in Q1 2026, its #273 holding.
Hanson & Doremus Investment Management first reported a position in GSK in Q2 2013 and has held it in 48 quarters since.
Hanson & Doremus Investment Management's GSK position peaked at $1.68M in Q4 2019.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Hanson & Doremus Investment Management's 13F filing for Q1 2026, filed 17 Apr 2026.